Global Market Size, Forecast, and Trend Highlights Over 2025-2037
CRISPR & Cas Genes Market size was over USD 4.9 billion in 2024 and is estimated to reach USD 35.28 billion by the end of 2037, expanding at a CAGR of 16.4% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of CRISPR & cas genes is assessed at USD 5.54 billion.
Heightening incidences of genetic disorders and abnormal mutation worldwide are pushing biotech pioneers to engage their resources in the CRISPR & cas genes market to draft a more personalized approach to cure. Over 7000 types of genetic conditions were identified around the globe, where the occurrence of a single type ranged between 3.5% and 5.9%: 2022 Genetics in Medicine Journal. Another 2020 NLM article predicted that the genetic prevalence of autosomal recessive (AR) inherited retinal diseases (IRDs) was affecting 5.5 million habitats globally. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has become a revolutionary method to produce such targeted therapies to combat the widespread.
Further, the contribution of the CRISPR & cas genes market in reducing production costs and enhancing the efficacy of cell-based therapeutics is attracting investors. The cost per patient may vary as per the target, application, and development process of the genomic therapies. As per an NLM report, published in November 2023, the prior batch of these offerings was priced up to USD 3.5 million (for individual treatment). It also put an example of sickle cell disease (SCD) therapy, costing each patient USD 1.0 million. It signifies the growing need for extensive capital influx and government support to make them more accessible and affordable for widespread use. Thus, the genome industry is now encouraging innovations in this field to mitigate the high payers’ pricing tag from associated therapies.
Payers’ Pricing of Selected FDA-approved Genomic Therapies
|
Therapy |
Type |
Price (in USD) |
|
TECARTUS |
Autologous CAR T Cells |
373,000.0 |
|
BREYANZI |
Autologous CAR T Cells |
410,300.0 |
|
ABECMA |
Autologous CAR T Cells |
419,500.0 |
|
CARVYKTI |
Autologous CAR T Cells |
465,000.0 |
|
ZYNTEGLO |
Autologous HSP Cells |
2,800,000.0 |
|
SKYSONA |
Autologous HSP Cells |
3,000,000.0 |
|
HEMGENIX |
Factor IX (FIX-Padua) Gene |
3,500,000.0 |
Source: 2022 NLM Report
CRISPR & Cas Genes Sector: Growth Drivers and Challenges
Growth Drivers
- Rising focus and investments in genomic therapy: As the demand for personalized medicine rises, investments in the CRISPR & cas genes market inflate. Many research-based pharmaceutical companies and public health authorities are now developing interest in this field to gain the ability to customize and enhance the genetic profiles and specificity of drugs. For instance, in July 2023, researchers from Duke University and the University of California San Diego introduced two different CRISPR-based therapeutic pathways, APOE-e4 and beta-amyloid, for treating Alzheimer's. Great improvements in outcomes were displayed at the Alzheimer’s Association International Conference, held in Amsterdam, Netherlands, encouraging others to work in this category.
- Advancements in genetic editing technologies: The contribution of gene editing technologies in the escalation of the understanding of heterogeneity in certain medical conditions is influencing MedTech pioneers to develop new platforms and tools. These tech-based laboratory solutions further leverage the quality and efficacy of products from the CRISPR & cas genes market. On this note, in January 2022, Bayer AG paid USD 40.0 million upfront cash to Mammoth Biosciences for accessing its novel CRISPR systems to produce in vivo gene-editing therapies. Such innovations are fueling progression in the genome editing industry, which is predicted to reach USD 10.5 billion by 2025 and USD 66.6 billion by 2037, exhibiting a 16.2% CAGR: Research Nester.
Challenges
- Limitations in drug delivery systems: Finding the right method or carrier for the components, induced by the researchers associated with the CRISPR & cas genes market, is still a challenge. In-efficiency of existing solutions, such as viral vectors and nanoparticles, often causes delays and safety concerns. The absence of appropriate systems may also result in unintended genetic modifications, harming mutational properties and immune response. These factors may create barriers against the exponential growth of this field.
- High competency and volatility: There is a risk of fostering legal disputes and uncertainty on proprietorship of intellectual properties due to the highly competitive landscape of the CRISPR & cas genes market. The ongoing battles between biotech companies and research institutions in advancing may develop a hard-to-concur environment for newcomers. This further restricts diversity in this field, limiting productivity and frequency of discoveries. Moreover, the disparities in supply and distribution channels may hinder availability and market expansion.
CRISPR & Cas Genes Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
16.4% |
|
Base Year Market Size (2024) |
USD 4.9 billion |
|
Forecast Year Market Size (2037) |
USD 35.28 billion |
|
Regional Scope |
|
CRISPR & Cas Genes Segmentation
End use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations (CROs), Others)
Biotechnology & pharmaceutical companies segment is estimated to capture CRISPR & cas genes market share of over 53.4% by 2037. The rapid surge in commercial usage for developing personalized medications is propelling growth in this segment. This is further testified by the remarkable expansion of the precision medicine industry, which is projected to attain USD 113.6 billion by 2025 and USD 757.4 billion by 2037 with a CAGR of 16.7%. In addition, the segment is augmented under the positive influence of increasing R&D investments and the integration of artificial intelligence (AI). In this regard, a 2024 Frontiers study observed new insights, capabilities, and opportunities during genetic code modifications in CRISPR-Cas-associated nucleases with AI, signifying the segment’s progress.
Application (Biomedical, Agricultural)
In terms of applications, the biomedical segment is projected to register a noteworthy share in revenue from the CRISPR & cas genes market throughout the forecasted timeframe. This type of gene alteration is highly preferred for therapeutic advances due to its versatility, effectiveness, and ease of use. Ongoing biopharma discoveries have notably marked their significance in various medical disciplines and clinical trials. An NLM study from August 2023 identified the biomedical research industry as the major field of application, developing targeted gene knockouts, disease models, and potential therapeutic strategies. Furthermore, the high utility of CRISPR & cas genes in understanding heterogeneity and chromosomal mechanisms of certain medical conditions is influencing MedTech pioneers to invest in this segment.
Our in-depth analysis of the CRISPR & cas genes market includes the following segments:
|
End use |
|
|
Application |
|
|
Product & Service |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCRISPR & Cas Genes Industry - Regional Synopsis
North America Market Analysis
By 2037, North America CRISPR & cas genes market is set to capture over 44.2% revenue share. The region presents a large pool of participants for this sector, attributable to its excellence in genomic alterations, clinical data sharing, and drug discovery. According to Research Nester, this region is estimated to become the largest contributor to revenue generation in the DNA sequencing industry with a 51.5% share by 2037. Strategic international collaborations and growing demand in advanced agriculture are also fueling growth in this marketplace. For instance, in May 2024, Pairwise extended its global partnership with Bayer to escalate the reach of its portfolio of CRISPR-based edible goods across North America by upscaling the volume of production and commercialization.
The U.S. is one of the forefront holders of the CRISPR & cas genes market due to its large consumer base and wider channels of applications. The well-established healthcare and biomedical R&D infrastructure of this country is fostering a favorable business environment for global pioneers. In addition, the supportive regulatory framework is playing a crucial role in broadening the adoption range. For instance, in December 2023, the U.S. FDA issued clearance for Casgevy and Lyfgenia for treating sickle cell disease (SCD) in residents aged 12 and older. The approval opened new gateways for novel genome editing technologies and related products, propelling innovation in this merchandise.
Canada is also propagating the CRISPR & cas genes market with government initiatives. With a rapid expansion of the domestic territory of the genome sequencing category, the nation is empowering its emphasis on biomedical advancements and accessibility of therapeutics. On this note, in October 2023, the government of Canada allocated a USD 15.0 million fund for constructing a Pan-Canadian Genome Library. This was intended to make access to genomic data easier for both academia and commercial use. This is evidence of a continuous capital influx in this sector, acting as a financial cushion for future discoveries and analytical excellence, feeding growth in local service providers.
APAC Market Statistics
Asia Pacific is predicted to experience the fastest growth pace in the CRISPR & cas genes market during the assessed period. Both agricultural and biomedical demand is fueling this region’s leadership. Rapid emergence in the bioeconomy has positively influenced this merchandise to expand, making it an attractive landscape of trading for global leaders. For instance, in June 2021, Merck’s patent application for its proxy-CRISPR technology was approved by the Japanese Patent Office. This success in authentication widened the reach of the company's genome coverage towards the untapped sections of this country. This indicates the growing interest in foreign forces for greater investments.
India is a large consumer of the agriculture segment in the CRISPR & cas genes market. There is a heavy use of this gene editing tool in improving productivity and quality of farm-based goods. This is also backed by government support, which was highlighted by the PIB press release from November 2022, mentioning a new finding. It stated that a group of scientists at Raman Research Institute (RRI) found a possibility of CRISPR gene-editing in temperature-sensitive organisms, plants, and crops. The scope of development in this country is also signified by its progress in bioeconomy, showcasing a potential to achieve USD 300.0 billion by 2030 (2022 IBEF report).
China is creating new channels of distribution and business opportunities for the CRISPR & cas genes market. In parallel with its neighboring biotech forces, the country is welcoming advanced technologies and MedTech innovations to empower its healthcare and agronomy. For instance, in April 2023, Shandong BellaGen Biotechnology gained a safety certificate for gene-editing in high oleic acid soybeans from the Ministry of Agriculture and Rural Affairs (MOA) in China. This approval initiated the industrial use of this technique on a large scale across the country, inspiring others to affiliate this field with their resourceful participation. Furthermore, China is also proactively incorporating CRISPR-cas9 assets in the medical field.
Companies Dominating the CRISPR & Cas Genes Landscape
- Thermo Fisher Scientific
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Illumina
- Agilent Technologies
- Synthego
- Danaher
- Origene Technologies
- GenScript
- Lonza
- Revvity, Inc.
- Merck KGaA
- Mammoth Biosciences, Inc.
- Regeneron Pharmaceuticals, Inc.
Considering the higher utility in the medical industry, key players are majorly focused on engaging their offerings in the pharmaceutical segment in the CRISPR & cas genes market. They are actively developing new applications and therapeutics for wider adoption. For instance, in January 2024, CRISPR Therapeutics attained FDA approval for using CASGEVY (exagamglogene autotemcel) as a streamlined curative for transfusion-dependent beta-thalassemia. This CRISPR/Cas9 gene-edited cell therapy has been proven to be highly effective for residents aged 12 and over. Simultaneously, many other biopharmaceutical pioneers are participating in this cohort by introducing more efficient approaches. Such key players are CRISPR & cas genes market:
In the News
- In January 2025, Mammoth Biosciences released promising results from the preclinical research on its ultra-compact CRISPR system, NanoCas, in the preprint server of bioRxiv. The results presented its excellent abilities in extrahepatic editing by using a single adeno-associated viral (AAV) vector.
- In April 2024, Regeneron Pharmaceuticals collaborated with Mammoth Biosciences to accelerate research, development, and commercialization of in vivo CRISPR-based gene editing therapies by using next-generation technology. As per the agreement, Mammoth received a total upfront payment and equity investment of USD 100.0 million.
Author Credits: Radhika Pawar
- Report ID: 3287
- Published Date: Mar 27, 2025
- Report Format: PDF, PPT
